BioPharma US Partners, LP is a private equity fund based in New York, New York. According to its most recent Form D, filed Feb 15, 2012, it has sold $155,508,701 of interests to 34 investors since its first sale in Jun 2009. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. Related persons named in the filing include Pedro Gonzalez de Cosio; Pablo Legoretta; Benjamin Schliemann.
- Total raised
- $155,508,701Cumulative sales reported on Form D
- Investors
- 34
- First sale
- Jun 26, 2009
- Minimum investment
- None set
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Other exemption
- Key people and entities
- Pedro Gonzalez de Cosio; Pablo Legoretta; Benjamin Schliemann
- Latest Form D
- Feb 15, 2012
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Vehicles of this fund (2)
| Legal name on Form D | SEC CIK | Location reported | Total raised | Investors | Minimum | Latest Form D |
|---|---|---|---|---|---|---|
| BioPharma US Partners, LP (main vehicle on this page) | 1542088 | New York, New York | $155,508,701 | 34 | $0 | Feb 15, 2012 |
| BioPharma Cayman Partners, LP | 1468203 | New York, New York | $21,250,000 | 6 | $100,000 | Jul 13, 2009 |
Funds are often offered through several legal vehicles, such as onshore, offshore, feeder, parallel or tax-exempt versions, and each one files its own Form D. These 2 filings carry the same name apart from such vehicle words or a series letter and report the same location or the same adviser, so AltMountain shows them on one page; the details above are those of BioPharma US Partners, LP, the vehicle reporting the most raised. Each row is that vehicle's own filing, exactly as filed. The amounts should not be added together, because a feeder's money can also be counted in its master fund. Grouped by AltMountain from the filings; not confirmed by the fund. The CIK links open each vehicle's filings on SEC.gov. Source: SEC Form D filings.
Questions about BioPharma US Partners, LP
What is the minimum investment for BioPharma US Partners, LP?
BioPharma US Partners, LP's latest Form D, filed Feb 15, 2012, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in BioPharma US Partners, LP?
BioPharma US Partners, LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7).
How much has BioPharma US Partners, LP raised?
BioPharma US Partners, LP reports $155,508,701 sold from 34 investors on its Form D filed Feb 15, 2012. This is cumulative sales since the offering began, not current assets or performance.
Where is BioPharma US Partners, LP based?
BioPharma US Partners, LP is based in New York, New York.
When did BioPharma US Partners, LP launch?
BioPharma US Partners, LP reports its first sale in Jun 2009.
Size compared with every private equity fund
Raised more than 81% of the 3,669 private equity funds based in New York, and more than 78% of all 8,950 that report sales.